The FDA says its safety review of mifepristone will continue into next year, with a final report expected by March 2027. The review was prompted by a court order and is part of an ongoing agency process. No final decisions have been made. A state lawsuit alleges mail delivery undermines abortion bans. Critics have made allegations about the administration's stance, but no official assessment has been issued.
Key points
The FDA confirms that its evaluation of the primary abortion medication will extend beyond this year.
In a Wednesday legal document, the FDA provided a mandated update on its review progress. The review was initiated by the agency and is part of a reevaluation ordered by the FDA.
The FDA first authorized mifepristone in the year 2000. The agency has consistently validated the pill’s safety and performance throughout the years. Several limits on the drug have been lifted, such as removing the need for in-person pickup.
The FDA expects to complete a safety study by mid-December 2026. Officials anticipate releasing a report by March 2027 at the latest.
No final decisions have been made about new restrictions or changes to the drug’s use.
A federal judge ordered the FDA’s change after Louisiana sued, claiming mail-based mifepristone use weakens its abortion law.
This case is one of several state lawsuits related to mifepristone currently in court. Last month, a three-judge panel issued a ruling in a related case.
An official statement from the FDA does not include any assessment of the administration’s stance on the pill or its impact on women's health.
Gavin Oxley of Americans United for Life criticized the review, calling it a lack of 'true leadership' by Trump administration officials. He claimed the administration remains out of step with women's health needs and shows no intent to reduce the persistent damage from the abortion pill.
This claim is an allegation and has not been verified by the FDA or any official body.
In the United States, abortion most frequently uses the combination of mifepristone and misoprostol.
The review is ongoing and no final decisions have been made.
Spotted a mistake? Report an error · Corrections policy
From the newsroom
Newsroom desk
Trump promotes personal power at a Kentucky rally ahead of midterms, citing claims of renaming geographic features and reshaping language, though these actions are not verified by official records. Public frustration over economic policies persists amid growing protests and early voting efforts.
By News Desk ·
Vance on economy and future run in Michigan town hall
By News Desk ·
The rally occurred on Tuesday, October 13, 2026, at the Curtis D. Menard Memorial Sports Center, about 45 miles north of Anchorage. President Donald Trump flew eight hours to attend and called Senator Dan Sullivan 'one of the best and most respected senators in D.C.' Sullivan is seeking a third term in the Senate race against Democrat Mary Peltola, a former congresswoman. The event underscores the competitiveness of the Senate race in Alaska, which has historically been a Republican stronghold. Alaska has not backed a Democrat for Senate in nearly 20 years. Trump’s visit is part of a western swing that also includes rallies in Arizona and Montana. The Associated Press reported the visit and Trump’s remarks, citing a photo from the rally. An opinion is that the visit signals growing GOP concern about retaining control of Congress.
By News Desk ·
